Why isn't there separate SaaS pricing for developing countries?

It’s not (only) greed: “separate pricing” breaks in practice

Many STEM founders assume SaaS pricing should mirror pharma “tiered pricing”: lower prices in lower-income countries. In pure software, that idea runs into structural problems that are especially sharp in medtech (digital health, clinical workflow tools, AI decision support, device software).

The core issue: SaaS isn’t a one-time shipped good. It’s an ongoing service with recurring costs (hosting, security, support, compliance, product updates). When you create a “developing country” price, you also create a second product reality—different contracts, different enforcement, different risk—and the overhead can erase the benefit.

Five reasons separate developing-country pricing is rare

1) Arbitrage: the “cheap license” leaks into high-price markets

Arbitrage means customers buy at the low price and use/resell in the high-price region. With SaaS, this can happen through:

• Remote teams (a US hospital group with an offshore entity “buying” the license)
• VPN + cloud access (location is easy to spoof)
• Multi-site health systems (one contract used across countries)
• Channel partners (resellers bundling your tool into higher-priced offerings)

To prevent arbitrage, you need enforcement: geo-restrictions, identity checks, contract policing, audits. That’s expensive and can create a bad user experience—especially for clinicians who just want the tool to work.

2) Compliance and liability costs don’t scale down with GDP

In medtech SaaS, your cost base is not just servers. If your product touches clinical decisions, patient data, or regulated workflows, you may need:

• Quality management (e.g., design controls, change control, documentation)
• Privacy/security (risk assessments, incident response, audits)
• Clinical evaluation (evidence generation, post-market monitoring)
• Regulatory strategy (FDA 510(k), De Novo, or PMA depending on risk; plus non-US pathways)

Those costs are largely fixed. A “low-income country” customer can generate the same (or higher) support and risk burden as a high-income customer. If you price too low, you may be subsidizing risk you can’t afford—one adverse event, one security incident, or one regulatory complaint can be existential for an early-stage company.

3) Hospital procurement and reimbursement don’t map cleanly to “country”

In medtech, the buyer is often not the end user. Procurement is shaped by:

• Hospital purchasing committees and tender processes
• Budget silos (IT vs clinical department vs innovation fund)
• Reimbursement (whether there are CPT codes, DRGs, or local payment mechanisms—often “varies” widely)

Two hospitals in the same country can have radically different ability to pay. A single “developing country price” can be simultaneously too high for public hospitals and unnecessarily low for private systems. That’s why many SaaS companies prefer segmentation by customer type (public vs private, academic vs community, clinic vs tertiary center) rather than by passport.

4) Support, onboarding, and integration costs can be higher in under-resourced settings

Founders often underestimate the non-software work required to make clinical SaaS usable:

• Workflow mapping (how orders, notes, and results actually move)
• Integrations (EHR/LIS/PACS; HL7/FHIR interfaces; SSO)
• Training (rotating staff, multiple languages, limited protected time)
• Infrastructure constraints (bandwidth, device availability, intermittent power)

If you charge less but spend more time per deployment, your gross margin collapses. Many SaaS businesses survive on high gross margins that fund R&D and compliance. If margins drop, product quality and safety can degrade—bad for patients and for you.

5) “Developing country” is a blunt label that creates reputational and legal risk

Tiered pricing can trigger backlash from both sides:

• High-price markets: “Why am I subsidizing others?”
• Low-price markets: “Why are you labeling us?” or “Why is support worse?”

Also, defining eligibility is messy. Do you use World Bank categories? Per-capita income? Facility type? NGO status? Any rule creates edge cases and disputes, which means more legal work and slower sales cycles.

Why medtech makes this harder than generic SaaS

In consumer SaaS, you can often offer a student plan and call it a day. In medtech, pricing is entangled with risk and clinical accountability. If your software is considered Software as a Medical Device (SaMD) or influences diagnosis/therapy, you may face:

• Regulatory expectations (FDA pathway depends on intended use and risk; 510(k) vs De Novo vs PMA)
• Clinical governance (hospital committees, IRB if you’re studying outcomes)
• Data obligations (patient privacy, retention, breach notification)

These obligations don’t get cheaper because the customer is in a lower-income region. In fact, if local regulations are less clear, your risk can increase because you’re operating without well-trodden playbooks.

Better alternatives: equitable pricing that still works

If your goal is access (and it should be, in healthcare), you can design pricing that is harder to arbitrage and aligned to value without relying on a simplistic “developing country” discount.

Option A: Segment by facility type and use case (not geography)

Examples of segments that map to ability-to-pay and value:

• Public hospital vs private hospital
• Primary care clinic vs tertiary referral center
• Academic medical center (research-heavy) vs community hospital (throughput-heavy)
• Single site vs multi-site network

This also matches procurement reality: tenders and budgets are often defined by facility class.

Option B: Price on measurable value units

Instead of “per country,” price per unit that correlates with benefit and cost-to-serve:

• Per active clinician (works for workflow tools)
• Per study / per protocol (research platforms)
• Per device (connected device software)
• Per site with integration tiers (basic vs integrated)

Value-based pricing is business jargon for “price based on the outcome/value delivered, not your cost.” In medtech SaaS, you can anchor value to time saved, reduced readmissions, fewer adverse events, or improved throughput—then translate that into a pricing metric that procurement can understand.

Option C: Offer “access programs” with strict eligibility and non-transferability

If you truly want low-income access, treat it like a program, not a price list:

• Eligibility via NGO/public status or specific service lines (e.g., maternal health clinics)
• Contractual non-transfer clauses and audit rights
• Feature parity (avoid “second-class” safety)
• Clear support boundaries (e.g., community support + paid premium support)

This reduces reputational risk: you’re not saying “your country is cheap,” you’re saying “this program supports specific care settings.”

Option D: Separate software price from services price

Many deployments fail because founders bundle everything into one subscription. Consider:

• Low software subscription (recurring)
• Implementation fee (one-time; can be waived via grants/partners)
• Integration add-ons (HL7/FHIR, SSO, custom reporting)

This is often more “fair” across regions because the biggest cost driver is implementation effort, not the license itself.

Option E: Partner-led distribution (local integrators, ministries, or NGOs)

In many countries, the fastest route is not direct SaaS sales but a partner who already sells into the health system. You may accept lower per-site revenue in exchange for:

• Lower customer acquisition cost (CAC)
• Shared support burden
• Better procurement navigation

CAC is the total cost to win a customer (sales time, marketing, pilots). In medtech, CAC can be high because sales cycles are long and stakeholders are many.

What to do next

1. Map your cost-to-serve: list the recurring costs per customer (hosting, support hours, compliance work, integrations) and identify what actually scales with usage vs what is fixed.
2. Choose 2–3 segments based on procurement reality (e.g., public hospitals, private networks, NGOs) and write a one-paragraph “value story” for each.
3. Pick a pricing metric that is hard to arbitrage (per site, per active clinician, per device) and define what counts in plain language.
4. Create an access program if mission-critical: eligibility rules, contract terms, and a support model that won’t sink your team.
5. Pressure-test with real buyers (procurement + clinical champion) before publishing pricing; use structured interviews to learn what line items they can actually approve.

If you want to sanity-check your segmentation and pricing page, run it through /roast or compare how competitors package value in /Competitor_study.